UniQure Stock Surges 81% as FDA Does About-Face on Gene Therapy Treatment
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The FDA has reversed its stance on a gene therapy treatment, prompting a significant increase in UniQure's stock price. The stock surge is reported to be 81 percent. This change in the FDA's position has had a substantial impact on the company's stock.